USPTO Patent Application for ABHD6 Antagonist Drug

ChangeBridge: Patent Apps - Pharma (A61K)

Published September 29th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083735A1) filed by ONO Pharmaceutical Co., Ltd. on September 29, 2023. The application describes a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which exhibits ABHD6 inhibitory activity. This compound is intended for use as an active ingredient in pharmaceuticals for the prevention and/or treatment of diseases associated with ABHD6.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in drug discovery within the pharmaceutical sector. Companies involved in related research and development may wish to monitor the progress of this patent application and similar innovations in the field of ABHD6 inhibitors.

Source document (simplified)

← USPTO Patent Applications

ABHD6 ANTAGONIST

Application US20260083735A1 Kind: A1 Mar 26, 2026

Assignee

ONO PHARMACEUTICAL CO., LTD.

Inventors

Atsushi YOSHIDA, Ryuichi HYAKUTAKE, Nozomu NAGASHIMA, Ryosuke MISU, Shohei MORI

Abstract

A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.